News & Updates

Show Multimedia Only

Belzutifan-lenvatinib bests cabozantinib for RCC

11 Mar 2026 by

A combination regimen comprising belzutifan and lenvatinib outdoes cabozantinib alone for the treatment of advanced clear cell renal cell carcinoma (ccRCC) in the phase III LITESPARK-011 study.

Belzutifan-lenvatinib bests cabozantinib for RCC

11 Mar 2026

Angiotensin-II stimulating agents associated with lower burden of key AD neuropathologies

11 Mar 2026 by

Cumulative angiotensin II–stimulating (vs angiotensin II–inhibiting) antihypertensive exposure is associated with lower risk of certain dementia-related neuropathologies, a US study has found.

Angiotensin-II stimulating agents associated with lower burden of key AD neuropathologies

11 Mar 2026

Tafamidis beneficial in geriatric transthyretin cardiac amyloidosis

10 Mar 2026

Treatment with the transthyretin stabilizer tafamidis helps lower mortality and reduce hospital readmissions for acute heart failure in octogenarian patients with transthyretin cardiac amyloidosis, as shown in a study.

Tafamidis beneficial in geriatric transthyretin cardiac amyloidosis

10 Mar 2026

Direct nirsevimab shot may confer greater infant RSV protection than maternal RSVpreF vax

10 Mar 2026 by

Administering the monoclonal antibody nirsevimab directly to infants may be more protective than immunization via maternal RSV prefusion F protein (RSVpreF) vaccination, being associated with lower risks of RSV-related hospitalizations and severe outcomes in a real-world setting.

Direct nirsevimab shot may confer greater infant RSV protection than maternal RSVpreF vax

10 Mar 2026

Novel drug safe, efficacious in patients with HDV-related advanced liver disease

10 Mar 2026

Treatment with REP 2139-Mg (REP), a nucleic acid polymer, demonstrates efficacy and an acceptable safety profile among patients with hepatitis D virus (HDV) and advanced chronic liver disease (CLD), reports a recent study.

Novel drug safe, efficacious in patients with HDV-related advanced liver disease

10 Mar 2026

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

10 Mar 2026

Treatment with the oral interleukin-1β blocker diacerein appears minimally beneficial for reducing pain in patients with knee osteoarthritis (OA), as shown in a study.

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

10 Mar 2026

Nifedipine as good as labetalol for managing hypertension during pregnancy

10 Mar 2026 by

Treatment with either nifedipine or labetalol is equally effective in controlling blood pressure (BP) among women with hypertension during pregnancy, with no adverse effects on perinatal outcomes, according to the Giant PANDA* trial presented at SMFM 2026.

Nifedipine as good as labetalol for managing hypertension during pregnancy

10 Mar 2026

Finerenone shows promise for restoring fertility in premature ovarian insufficiency

10 Mar 2026 by

In patients with premature ovarian insufficiency (POI), finerenone, a drug approved for slowing progressive kidney function decline associated with type 2 diabetes, can promote the development of follicles into mature oocytes yielding viable embryos, according to breakthrough findings by researchers from the University of Hong Kong (HKU).

Finerenone shows promise for restoring fertility in premature ovarian insufficiency

10 Mar 2026

Meta-analyses of global GLP-1 RA studies highlight safety and new potential role of GLP-1 RAs

10 Mar 2026 by

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with diabetes or heart diseases is not associated with increased risk of optic nerve or vision-threatening events, and plays a role in improving the long-term success rate of curative catheter ablation for atrial fibrillation (AF) in cardiac patients with obesity, researchers from the University of Hong Kong (HKU) have found.

Meta-analyses of global GLP-1 RA studies highlight safety and new potential role of GLP-1 RAs

10 Mar 2026

Frontline tislelizumab plus chemo shows sustained survival advantage in NPC

09 Mar 2026

In the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), the combination of tislelizumab plus chemotherapy confers sustained survival benefit, according to 3-year data from the RATIONALE-309 trial.

Frontline tislelizumab plus chemo shows sustained survival advantage in NPC

09 Mar 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Belzutifan-lenvatinib bests cabozantinib for RCC

Belzutifan-lenvatinib bests cabozantinib for RCC

Angiotensin-II stimulating agents associated with lower burden of key AD neuropathologies

Angiotensin-II stimulating agents associated with lower burden of key AD neuropathologies

Tafamidis beneficial in geriatric transthyretin cardiac amyloidosis

Tafamidis beneficial in geriatric transthyretin cardiac amyloidosis

Direct nirsevimab shot may confer greater infant RSV protection than maternal RSVpreF vax

Direct nirsevimab shot may confer greater infant RSV protection than maternal RSVpreF vax

Novel drug safe, efficacious in patients with HDV-related advanced liver disease

Novel drug safe, efficacious in patients with HDV-related advanced liver disease

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

Oral interleukin-1β blocker makes no difference in knee osteoarthritis

Nifedipine as good as labetalol for managing hypertension during pregnancy

Nifedipine as good as labetalol for managing hypertension during pregnancy

Finerenone shows promise for restoring fertility in premature ovarian insufficiency

Finerenone shows promise for restoring fertility in premature ovarian insufficiency

Meta-analyses of global GLP-1 RA studies highlight safety and new potential role of GLP-1 RAs

Meta-analyses of global GLP-1 RA studies highlight safety and new potential role of GLP-1 RAs

Frontline tislelizumab plus chemo shows sustained survival advantage in NPC

Frontline tislelizumab plus chemo shows sustained survival advantage in NPC